Recombinant antibody-enzyme fusion proteins

Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide


Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0


424 943, 514 12, 435188, 5303881, 5303882, 5303388, 53038885, 530866, 530867, 530324, A61K 39395, A61K 4716, C12N 996




The invention is related to recombinantly produced fusion polypeptides comprising antibody V.sub.H and V.sub.L sequences operatively linked to a .beta.-lactamase for use in the delivery of cytotoxic drugs to tumor cells.

patent: 4975278 (1990-12-01), Senter et al.
Yeh et al., "Cell Surface Antigens of Human Melanoma identified by Monoclonal Antibody," Proc. Natl. Acad. Sci. USA 76:2927-2931 (Jun., 1979).
Woodbury et al., "Identification of a Cell Surface Protein, p97, in Human Melanomas and Certain Other Neoplasms," Proc. Natl. Acad. Sci. USA 77:2183-2187 (Apr., 1980).
Brown et al., "Quantitative Analysis of Melanoma-Associated Antigen p97 in Normal and neoplastic Tissues," Proc. Natl. Acad. Sci. USA 78:539-543 (Jan., 1981).
Brown et al., "Structural characterization of Human Melanoma-Associated Antigen p97 with Monoclonal Antibodies," J. Immunol. 127:539-546 (Aug., 1981).
Bosslet et al., "Molecular and Functional Characterisation of a Fusion Protein Suited for Tumour Specific Prodrug Activation," Br. J. Cancer 65:234-238 (1992).
Goshorn et al., "Genetic Construction, Expression, and Characterization of a Single Chain Anti-Carcinoma Antibody Fused to .beta.-Lactamase," Cancer Res. 53:2123-2127 (May 1, 1993).
Senter et al., "Generation of Cytotoxic Agents by Targeted Enzymes," Bioconjugate Chem. 4:3-9 (1993).
DeSutter et al., "A bifunctional Murine::Human Chimeric Antibody with One Antigen-Binding Arm Replaced by Bacterial .beta.-Lactamase," Mol. Immunol. 31:261-267 (1994).
Bosslet et al., "Tumor-Selective Prodrug Activation by Fusion Protein-Mediated Catalysis," Cancer Res. 54:2151-2159 (Apr. 15, 1994).
Wallace et al., "Intratumoral Generation of 5-Fluorouracil Mediated by an Antibody-Cytosine Deaminase Conjugate in Combination with 5-Fluorocytosine," Cancer Res. 54:2719-2723 (May 15, 1994).
Jungheim and Shepherd, "Design of Antitumor Prodrugs: Substrates for Antibody Targeted Enzymes," Chem. Rev. 94:1553-1566 (1994).
Bagshawe et al., "Antibody Directed Enzyme Prodrug Therapy (ADEPT)," Ann. Oncol. 5:897-891 (1994).
Rodrigues et al., "Development of a Humanized Disulfide-Stabilized Anti-p185.sup.HER2 Fv-.beta.-Lactamase Fusion Protein for Activation of a Cephalosporin Doxorubicin Prodrug," Cancer Res. 55:63-70 (Jan. 1, 1995).
Svensson et al., "In Vitro and In Vivo Activities of a Doxorubicin Prodrug in Combination with Monoclonal Antibody .beta.-Lactamase Conjugates," Cancer Res. 55:2357-2365 (Jun. 1, 1995).
Kerr et al., "Regressions and Cures of Melanoma Xenografts Following Treatment with Monoclonal Antibody .beta.-Lactamase Conjugates in Combination with Anticancer Prodrugs," Cancer Res. 55:3558-3563 (Aug. 15, 1995).
Siemers et al., "Modifying the Specificity and Activity of the Enterobacter cloacae P99 .beta.-Lactamase by Mutagenesis within an M13 Phage Vector," Biochem. 35:2104-2111 (1996).
Siemers et al., "Construction, Expression, and Activities of L49-sFv-.beta.-Lactamase, a Single-Chain Antibody Fusion Protein for Anticancer Prodrug Activation," Bioconjugate Chem. 8:510-519 (1997).


Say what you really think

Search for the USA inventors and patents. Rate them and share your experience with other people.


Recombinant antibody-enzyme fusion proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Recombinant antibody-enzyme fusion proteins, we encourage you to share that experience with our community. Your opinion is very important and Recombinant antibody-enzyme fusion proteins will most certainly appreciate the feedback.

Rate now


Profile ID: LFUS-PAI-O-465727

All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.